Introduction: FH is an autosomal dominant disease of lipid metabolism. Hypercholesterolemia, xanthomas, and death from early coronary artery disease (CAD) are common in this disease due to a mutation in the LDLR, Apo-B100 or PCSK9 genes. Case report: A 4-year-old male patient with a very rare heterozygous c.1730G > C (p.Trp577Ser) variation in exon 12 of the low-density lipoprotein receptor (LDLR) gene that causes familial hypercholesterolemia (FH) was reported. As in this case, the heterozygous form may not show any symptoms in the first decade. This variation is region specific. Therefore, region-specific diagnostic criteria should be developed. Conclusion: We aimed to contribute to the literature on the development of diagnostic criteria by discussing the patient's condition with the clinical results.
References
1.
Blackhart BD, Ludwig EM, Pierotti VR, Caiati L, Onasch MA, Wallis SC, et al. Structure of the human apolipoprotein B gene. Journal of Biological Chemistry. 1986;261(33):15364–7.
2.
Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-Term Safety and Efficacy of Low-Density Lipoprotein Apheresis in Childhood for Homozygous Familial Hypercholesterolemia. The American Journal of Cardiology. 2008;102(9):1199–204.
3.
Havel RJ. Approach to the Patient with Hyperlipidemia. Medical Clinics of North America. 1982;66(2):319–33.
4.
Dogan M, Eroz R, H Y. The Known about Next-Generation Sequencing (NGS) (Review of the Literature. Düzce Tıp Fakültesi Dergisi/Duzce Medical Journal. 2017;19(1):27–30.
5.
Aykan HH. Primer hiperlipidemili hastaların değerlendirilmesi ve ailevi hiperkolesterolemili çocuklarda mutasyon taraması. In: Hacettepe Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim dalı Uzmanlık Tezi Ankara. 2010.
6.
Sözen MM, Whittall R, Öner C, Tokatlı A, Kalkanoğlu HS, Dursun A, et al. The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis. 2005;180(1):63–71.
7.
Goldstein JL, Brown MS. The LDL Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(4):431–8.
8.
MYANT N. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993;104(1–2):1–18.
9.
Varret M, Rabès JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, et al. A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32. The American Journal of Human Genetics. 1999;64(5):1378–87.
10.
TYBJARGHANSEN A, HUMPHRIES S. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 1992;96(2–3):91–107.
11.
Ldl-Reseptör KFAHH. Apolipoprotein-B100 (ApoB100) Ve PCSK9 (Proprotein convertase subtilin kexin9) Genmutasyonlarının Tespiti, Erciyes Üniversitesi, Tıp Fakültesi, Çocuk Beslenme Ve Metabolizma Bilim Dalı. Tıpta Uzmanlık. 2013;
12.
Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 1999;143(1):41–54.
13.
Daniels SR, Greer FR. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics. 2008;122(1):198–208.
14.
Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A, et al. Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology. 2018;34(9):1210–4.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
